Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma
Aging · 2023
DOI: 10.18632/aging.205089 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2023. Verfasst von Xiang Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, RNA, Long Noncoding, Esophageal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Precisely forecasting the prognosis of esophageal squamous cell carcinoma (ESCC) patients is a formidable challenge. Cuproptosis has been implicated in ESCC pathogenesis; however, the prognostic value of cuproptosis-associated long noncoding RNAs (CuRLs) in ESCC is unclear. METHODS: Transcriptomic and clinical data related to ESCC were sourced from The Cancer Genome Atlas (TCGA). Using coexpression and Cox regression analysis to identify prognostically significant CuRLs, a prognostic signature was created. Nomogram models were established by incorporating the risk score and clinical characteristics. Tumor Immune Dysfunction and Rejection (TIDE) scores were derived by conducting an immune landscape analysis and evaluating the tumor mutational burden (TMB). Drug sensitivity analysis was performed to explore the underlying molecular mechanisms and guide clinical dosing. RESULTS: Our risk score based on 5 CuRLs accurately predicted poorer prognosis in high-risk ESCC patients across almost all subgroups. The nomogram that included the risk score provided more precise prognostic predictions. Immune pathways, such as the B-cell receptor signaling pathway, were enriched in the datasets from high-risk patients. High TMB in high-risk patients indicated a relatively poor prognosis. High-risk patients with lower TIDE scores were found to benefit more from immunotherapy. High-risk patients exhibited greater responsiveness to Nilotinib, BI-2536, P22077, Zoledronate, and Fulvestrant, as revealed by drug sensitivity analysis. Real-time PCR validation demonstrated significant differential expression of four CuRLs between ESCC and normal cell lines. CONCLUSIONS: The above risk score and nomogram can accurately predict prognosis in ESCC patients and provide guidance for chemotherapy and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China.
- Department of Thoracic Surgery, Third Affiliated Hospital of Naval Medical University, Shanghai 201805, China.
Zitieren
APA
Zhang, X., Feng, N., Wu, B., Guo, Z., Pan, T., Tao, X., Zheng, H., & Zhang, W. (2023). Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma. Aging. https://doi.org/10.18632/aging.205089
Vancouver
Zhang X, Feng N, Wu B, Guo Z, Pan T, Tao X, et al. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma. Aging. 2023. doi:10.18632/aging.205089
BibTeX
@article{Zhang2023,
author = {Zhang, Xiang and Feng, Nan and Wu, Bo and Guo, Zishun and Pan, Tiewen and Tao, Xiandong and Zheng, Hongyang and Zhang, Wenxiong},
title = {Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.205089}
}
EUVIMED